News | Contrast Media | January 19, 2018

Focus will be on hospital-based products that could benefit from reduced renal toxicity

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization. The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals, a privately-held Lenexa, Kansas-based medical invention company that Ligand acquired in January 2018 for $2 million in cash plus earnouts.

Ligand CEO John Higgins explained that contrast agents are an important component of the diagnostic imaging market, however they can be toxic and are known to cause kidney damage in some patients. He added that Captisol is a specialized cyclodextrin that plays a role in protecting kidneys from the damaging effects of these agents. Captisol-enabled (CE) iohexol, marketed as Omnipaque by GE Healthcare, has been shown to prevent nephrotoxicity by more than 50 percent in animal models.1

The company said the initial internal program is focused on a CE formulation of iohexol given the large global market, lack of alternatives and focused development path for use in the cardiovascular setting. The initial CE-iohexol program will focus on partnering-enabling studies, with an estimated $6 million of program spend by Ligand over approximately three years.

For more information: www.ligand.com

References

1. Rowe ES, et al. Journal of Neuroimaging 2016; 26(5):511-8


Related Content

News | Ultrasound Imaging

September 15, 2023 — Contrast enhanced ultrasound (CEUS) is underutilized in the United States, and reduced access to ...

Time September 15, 2023
arrow
News | Prostate Cancer

July 28, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 28, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

July 27, 2023 — Scientists have found a new use for copper in magnetic resonance imaging (MRI) contrast agent design ...

Time July 27, 2023
arrow
News | Contrast Media

July 25, 2023 — Bracco Imaging has issued a statement on new results published in the journal Radiology which found that ...

Time July 25, 2023
arrow
News | Contrast Media

June 20, 2023 — Ascelia Pharma presented data from its Orviglance Hepatic Impairment study during the European Society ...

Time June 20, 2023
arrow
News | Contrast Media

May 16, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

Time May 16, 2023
arrow
News | Contrast Media

May 15, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced that ...

Time May 15, 2023
arrow
Feature | Contrast Media | By Christine Book

In the past year, the radiology community has been a first-hand, hands-on witness to myriad unexpected challenges and ...

Time May 03, 2023
arrow
News | Pediatric Imaging

April 28, 2023 — At the urging of the American College of Radiology (ACR) and others, the US Food and Drug ...

Time April 28, 2023
arrow
News | PET Imaging

March 23, 2023 — Nuclidium announced that the Neuroendocrine Tumors Research Foundation (NETRF) has selected the company ...

Time March 24, 2023
arrow
Subscribe Now